Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05502237 · ClinicalTrials.gov registry record · Phase 3
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer
A Phase 3 study of Non-Small Cell Lung Cancer, sponsored by Gilead Sciences.
- Active
- Registry status
- Phase 3
- Development phase
- 1,021
- Enrollment target
- 20
- Study locations
NCT05502237: Active Phase 3 study of Non-Small Cell Lung Cancer, sponsored by Gilead Sciences.
NCT05502237 is a Phase 3 study of Non-Small Cell Lung Cancer that is active but no longer recruiting, run by Gilead Sciences. The registered enrollment target is 1,021 participants, above the 650-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (57% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05502237, a Phase 3 study of Non-Small Cell Lung Cancer, is active but no longer recruiting, sponsored by Gilead Sciences.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,021 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to compare the effect of zimberelimab (ZIM) and domvanalimab (DOM) in combination with chemotherapy relative to pembrolizumab (PEMBRO) in combination with chemotherapy on overall survival (OS) in patients with untreated metastatic non-small cell lung cancer with no actionable genomic alteration.
Primary Outcome
OS is defined as the time from the date of randomization to the date of death from any cause.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Carboplatin
- DRUG Cisplatin
- DRUG Zimberelimab
- DRUG Domvanalimab
Study Locations (20)
Other
- Investigaciones CORI S.R.L. - Capital
- Centro Médico Privado Centro de Especialidades Médicas Ambulatorias e Investigación Clínica - Cardoba
- Sanatorio Allende - Córdoba
- Sanatorio Britanico de Rosario - Rosario
- Sanatorio Parque de Rosario - Rosario
- Hospital Provincial del Centenario - Rosario
- Instituto Medico de la Fundacion Estudios Clinicos - Rosario
- Clínica Viedma - Viedma
- Ordensklinikum Linz GmbH, Elisabethinen - Linz
California
- Innovative Clinical Research Institute - Whittier
District of Columbia
- George Washington Medical Faculty Associates - Washington D.C.
Florida
- Moffitt Cancer Center - Tampa
Illinois
- Illinois Cancer Care - Peoria
North Carolina
- Messino Cancer Centers - Asheville
Ohio
- Oncology Hematology Care, Inc. - Cincinnati
Oregon
- Hematology & Oncology Associates - Eugene
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,021 participants |
| Start Date | 2022-10-12 |
| Est. Completion | 2029-01 |
| Phase | Phase 3 |
What the registry record for NCT05502237 still lists
NCT05502237 is an interventional study that assigns participants to a tested intervention. Its 1,021 participants enrollment target places it among the larger protocols in the corpus, above the 650-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (57% higher).
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT05502237 names 20 study sites across 12 states, led by Other, California, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT05502237 about?
NCT05502237 is a clinical study titled "Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer". The primary objective of this study is to compare the effect of zimberelimab (ZIM) and domvanalimab (DOM) in combination with chemotherapy relative to pembrolizumab (PEMBRO) in combination with chemotherapy on overall survival (OS) in patients with untreated metastatic non-small cell lung cancer wit...
What is the current status of trial NCT05502237?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,021 participants. The study started on 2022-10-12. Estimated completion is 2029-01.
What conditions does trial NCT05502237 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT05502237?
The interventions under investigation include: Pembrolizumab (DRUG), Carboplatin (DRUG), Cisplatin (DRUG), Zimberelimab (DRUG), Domvanalimab (DRUG).
Who is sponsoring clinical trial NCT05502237?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05502237 being conducted?
This trial has 20 study locations across California, District of Columbia, Florida, Illinois, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05502237's enrollment target sits among peer trials
1,021 21st of 454 higher than 434 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
RECRUITING · Phase 3
-
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
RECRUITING · Phase 3
-
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
RECRUITING · Phase 3
-
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
RECRUITING · Phase 3
-
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02178163 · 1,020 participants · NA
Comprehensive Genomic Analysis in Tissue Samples From Patients With Recurrent or Stage IV Non-small Cell Lung Cancer
- NCT05225428 · 1,020 participants · NA
Video Education With Result Dependent dIsclosure
- NCT06697600 · 1,020 participants · NA
A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers
- NCT06760637 · 1,020 participants · Phase 3
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI